- Details
- Description
About Ivonescimab
Ivonescimab is the most advanced PD-1/VEGF bispecific antibody in clinical development in the U.S., Canada, Europe, Japan & Latin America and is an investigational therapy that is not approved by any regulatory authority other than China’s National Medical Products Administration (NMPA).
It brings two validated mechanisms in oncology3-5 into ONE novel tetravalent molecule. Ivonescimab simultaneously engages both PD-1 & VEGF. Globally over 1,800+ have been treated with ivonescimab across all clinical trials to date.
- Ivonescimab sold as brand name 依达方® in china.
Effect
Effect of ivonescimab monotherapy in patients with PD-L1-positive (PD-L1 TPS ≥1%) locally advanced or metastatic non-small cell lung cancer (NSCLC)
Dosage and administration
Ivonescimab is administered by intravenous infusion.
The recommended dose is 20 mg/kg, once every 3 weeks, until disease progression or unacceptable toxicity occurs.
When Ivonescimab is administered in combination with chemotherapy drugs, Ivonescimab should be given first, with an interval of at least 30 minutes, followed by chemotherapy drugs. See also the prescribing information for chemotherapy drugs.
Atypical efficacy responses may be observed (e.g., temporary tumor enlargement or new lesions in the first few months of treatment, followed by tumor shrinkage); if the patient's clinical symptoms are stable or continue to improve, even if there is preliminary evidence of disease progression on imaging, based on the judgment of overall clinical benefit, continued use of Ivonescimab treatment can be considered until disease progression is confirmed.
Interruption of dosing or permanent discontinuation may be necessary based on safety and tolerability in the individual patient. Dose increases or decreases are not recommended.
